Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy


Monday, Feb. 12 

Tuesday, Feb. 13

Wednesday, Feb. 14

Thursday, Feb. 15

Monday, Feb. 12 

Welcome and Keynote Lectures 
6:30-8:15 p.m.

Welcome Remarks
Conference Cochairs

Keynote Addresses

Differential Regulation of Inflammation in the Brain and Spinal Cord
Joan M. Goverman, University of Washington, Seattle, Washington

Systemic immune therapies for treating brain metastasis and their effects on the tumor microenvironment in the brain
Harriet M. Kluger, Yale University, New Haven, Connecticut

Opening Reception
8:30-10 p.m.

Tuesday, Feb, 13 

Continental Breakfast
7-8 a.m.

Plenary Session 1: Principles that govern unique aspects of the host immune response within the brain
Session Chair: Glenn F. Rall, Fox Chase Cancer Center, Philadelphia, Pennsylvania 
8-10 a.m.

CNS-draining lymphatics in regulation of meningeal immunity
​Antoine Louveau​, University ​of Virginia School of Medicine, Charlottesville, Virginia

Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment
Aaron Diaz, University of California, San Francisco, San Francisco, California

Modeling Cerebral Edema in Immunotherapy Recipients
Glenn Rall

Integrated omics analysis of temporal changes of neoantigen and tumor microenvironment in primary and recurrent gliomas*
Takahide Nejo, Department of Neurosurgery, The University of Tokyo, Tokyo, Japan

Contraction of T-cell richness in brain metastases of non-small cell lung cancers* 

Aaron Mansfield, Mayo Clinic, Rochester, Minnesota

10-10:30 a.m.

Plenary Session 2: The CNS Immunology: Effector Mechanism (The Efferent Arm of CNS Immunity)
Session Chair: Robyn S. Klein, Washington University School of Medicine, St. Louis, Missouri
10:30 a.m.-12:30 p.m.

Innate immune regulation of blood-brain barrier function
Robyn S. Klein

Regulatory programs mediated by lectins and glycans in CNS immunopathology
Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

Microglial responses at the blood-brain barrier
Dimitrios Davalos, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio

Intravital imaging of CAR-T cells directed against GD2 in a preclinical immunocompetent glioblastoma model*
Surya Murty, Stanford University, Stanford, California

Adoptive cell therapy for high-grade gliomas using simultaneous temozolomide and intracranial MGMT-modified γδ T cells following standard post-resection chemo and radiotherapy*
Lawrence Lamb, University of Alabama at Birmingham, Birmingham, Alabama

Poster Session A/Lunch
12:45-3:15 p.m.

Plenary Session 3: The CNS Tumor Microenvironment  
Session Chair: Hideho Okada, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
3:30-6 p.m.

Gliomas: Big data visualization and mouse modeling
Eric C. Holland, Fred Hutchinson Cancer Research Center, Seattle, Washington

Sex specific modifiers of brain tumor risk
Joshua B. Rubin, Washington University School of Medicine, McDonnell Genome Institute, Saint Louis, Missouri

Immunopathology of brain tumors: Relevance of immune infiltrates
Christel Herold-Mende, University of Heidelberg, Heidelberg, Germany

Neoantigens and mutation-induced immunoregulatory mechanisms in gliomas
Hideho Okada

Discrimination of response to CAR T-cell therapy using a novel response metric incorporating tumor growth kinetics in recurrent GBM patients*
Gustavo De Leon, Mayo Clinic, Phoenix, Arizona

Vascular niche regulates alternative macrophage activation in glioblastoma immunity*
Yi Fan, University of Pennsylvania, Philadelphia, Pennsylvania

Dinner on Own/Evening off
6 p.m.-

Top of page

Wednesday, Feb.​ 14 

Continental Breakfast
7-8 a.m.

Plenary Session 4: CNS Metastasis  
Session Chair: Patricia S. Steeg, National Cancer Institute, Bethesda, Maryland
8-10 a.m.

What is the status of blood-tumor barrier and immune cells in brain met models?
Patricia S. Steeg

Innate immunity in parenchymal and leptomeningeal metastasis: mechanism and therapeutic opportunities
Adrienne Boire, Memorial Sloan Kettering Cancer Center, New York, New York

The inflammatory microenviroment in brain metastases as a therapeutic target
Anna Berghoff, German Cancer Research Center, Heidelberg, Germany

Syndecan 1/IL-8 axis facilitates breast cancer brain metastasis through modulation of blood-brain barrier permeability*
Sierra Mosticone Wangensteen, Virginia Commonwealth University, Richmond, Virginia

Ligand-independent EphA2 signaling drives an amoeboid melanoma phenotype that metastasizes to the brain*
Inna Smalley, The Moffitt Cancer Center & Research Institute, Tampa, Florida

Plenary Session 5: Checkpoint Pathways Relevant to CNS  
Session Chair: Robert M. Prins, David Geffen School of Medicine at UCLA, Los Angeles, California
10:30 a.m.-12:30 p.m.

Challenges in testing Immunotherapies in clinical trials
Mark R. Gilbert, NCI-CCR, Bethesda, Maryland

Immune checkpoint biomarkers in CNS gliomas and metastasis
Amy B. Heimberger, The University of Texas MD Anderson Cancer Center, Houston, Texas

Immune checkpoint blockade in patients with melanoma metastatic to the brain
Kim A. Margolin, City of Hope, Duarte, California

Influence of PD-1 antibody blockade on the tumor microenvironment in patients with recurrent glioblastoma*
Aaron Mochizuki, University of California Los Angeles, Los Angeles, California

The immune landscape of PD-1 expression in human glioblastoma*
Alexander Lee, University of California Los Angeles, Los Angeles, California

Poster Session B/Lunch
12:45-3:15 p.m.

Plenary Session 6: Adoptive T cell Therapy for CNS Malignancies 
Session Chair: Christine Brown, City of Hope, Duarte, California
3:30-5:30 p.m.

Adoptively transferred T cells for primary and secondary CNS malignancies
Richard Sherry, National Cancer Institute, Bethesda, Maryland

CAR T cell immunotherapy of brain tumors and associated neurotoxicities
Michael C. Jensen, Seattle Children’s Research Institute, Seattle Washington

Neurotoxicity observed in CD19 CAR therapy
Hyam I. Levitsky, Juno Therapeutics, Seattle, Washington

New therapeutic approach for central nervous system lymphoma by CD19 CAR T cells*
Xiuli Wang, City of Hope National Medical Center, Duarte, California

Cloning and characterization of T-cell receptors reactive to the mutant isocitrate dehydrogenase-1-derived neoepitope in low-grade gliomas*
Payal Watchmaker, Department of Neurological Surgery, University of California San Francisco, San Francisco, California

Co-stimulatory domain 41BB (CD137) improves specificity and proliferative potential of IL13Ra2-specific CAR T cells for the treatment of glioblastoma*
Renate Starr, Beckman Research Institute, City of Hope National Medical Center, Duarte, California

Dinner on own/Evening off
5:30 p.m.-

Top of page

Thursday, Feb, 15 

Continental Breakfast
7–8 a.m.

Plenary Session 7: Viral Therapy
Session Chair: Noriyuki Kasahara, University of Miami Health System, Miami, Florida
8-10 a.m.

Oncolytic poliovirus immunotherapy
Matthias Gromeier, Duke University Medical Center, Durham, North Carolina

Oncolytic adenovirus: the immune angle
Juan Fueyo, The University of Texas MD Anderson Cancer Center, Houston, Texas

An oncolytic measles virus-sensitive group 3 medulloblastoma model in immune-competent mice*
Sangeet Lal, University of California San Francisco, San Francisco, California

Retroviral replicating vectors for tumor-targeted gene therapy and immunotherapy of glioma
Noriyuki Kasahara

Immunologic activation in recurrent high-grade glioma patients with durable complete response following treatment with Toca 511 and Toca FC*
Clark Chen, University of Minnesota, Minneapolis, Minnesota

10-10:15 a.m.

Plenary Session 8: Multi-modality Immunotherapy Approaches Targeting CNS Tumor Microenvironment
Session Chair: Ignacio Melero, University of Navarra, Pamplona, Spain
10:15 a.m.-12:15 p.m.

Radiation therapy and PD-1 blockade in brain metastasis from breast cancer
Silvia C. Formenti, Weill Cornell Medical College, New York, New York

Targeted and immunotherapeutic approaches in brain metastases
Frank A. Winkler, German Cancer Research Center, Heidelberg, Germany

Novel combinations: Neoadjuvant presurgery and dendritic cell vaccine for glioblastoma
Ignacio Melero

IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma*
Derek Wainwright, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Noninvasive monitoring of in situ immunotherapeutic responses in glioblastoma using novel PET and MRI techniques*
Joseph Antonios, University of California Los Angeles, Los Angeles, California

Closing Remarks
12:15-12:30 p.m.

*Short talk from proffered abstracts

Top of page